Document Detail


Foscarnet 5 versus 7 days a week treatment for severe gastrointestinal CMV disease in HIV-infected patients.
MedLine Citation:
PMID:  8740103     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In a randomized open trial foscarnet 90 mg/kg b.i.d. 5 days for 3 weeks was compared to 90 mg/kg b.i.d. daily in severe gastrointestinal cytomegalovirus disease in HIV-infected patients. Thirty-eight patients were randomized, 36 were evaluable (all male, age 24-54 years, median 40 years; CD4/microliter 0-150, median 10). Treatment efficacy was evaluated based on a score consisting of symptoms, endoscopic and histologic examination. In the 5-day treatment group 10/16 (62%) patients responded to treatment, in the 7-day treatment group 13/20 (65%), with symptoms resolving in most patients after 1 week. Side effects and adverse events were seen in 13 patients in the 5-day treatment group and in 15 patients in the 7-day treatment group. Laboratory abnormalities were common in both groups, in one patient reversible renal insufficiency developed. Efficacy and safety of treatment 5 days a week was comparable to the standard regimen.
Authors:
B Salzberger; A Stoehr; H Jablonowski; W Heise; U Ewald; K Peters; G Fätkenheuer; M Schrappe
Related Documents :
21881053 - Quality-of-life outcomes in transoral robotic surgery.
21812863 - Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor i...
20361213 - Excellent outcomes of laparoscopic esophagomyotomy for achalasia in patients older than...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Infection     Volume:  24     ISSN:  0300-8126     ISO Abbreviation:  Infection     Publication Date:    1996 Mar-Apr
Date Detail:
Created Date:  1996-11-12     Completed Date:  1996-11-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0365307     Medline TA:  Infection     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  121-4     Citation Subset:  IM; X    
Affiliation:
Klinik I für Innere Medizin, Universitätsklinik Köln, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Cytomegalovirus Infections / drug therapy*
Endoscopy
Foscarnet / administration & dosage*,  adverse effects,  therapeutic use
Gastrointestinal Diseases / drug therapy*,  virology*
HIV Infections / complications*
Humans
Male
Middle Aged
Chemical
Reg. No./Substance:
4428-95-9/Foscarnet

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Diminished T lymphocyte proliferative response to polyclonal mitogens in acute brucellosis patients.
Next Document:  Increased cerebrospinal fluid levels of glial fibrillary acidic protein (GFAp) in Lyme neuroborrelio...